Cargando…
Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
Covid-19 infection caused by the novel coronavirus SARS-COV-2 continues to be a major global health challenge. Till date, no drug has been approved for the treatment of this infection. A number of medications have been proposed and there are ongoing clinical trials around the world to find a suitabl...
Autores principales: | Owa, Adewale Bayode, Owa, Olufunke Tolulope |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247474/ https://www.ncbi.nlm.nih.gov/pubmed/32474026 http://dx.doi.org/10.1016/j.jmii.2020.05.014 |
Ejemplares similares
-
Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023) -
Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020) -
Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
Publicado: (2020) -
Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020) -
Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients
por: Zanon, D., et al.
Publicado: (2020)